Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer | Zendy

Vittorio Gebbia | Zendy; Gianfranco Mancuso | Zendy; Lucia Lombardi | Zendy; Evaristo Maiello | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer

Author(s) -

Vittorio Gebbia,

Gianfranco Mancuso,

Lucia Lombardi,

Evaristo Maiello

Publication year - 2009

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000258501

Subject(s) - medicine , lung cancer , pharmacogenomics , disease , intensive care medicine , oncology , chemotherapy , cancer , pharmacology

Advanced non-small cell lung cancer remains a lethal disease with poor prognosis. In the last decades results of systemic chemotherapy have reached a disappointing plateau without significant differences between the most widely employed third-generation regimens. Recent scientific evidence has shed new light on the management of advanced non-small cell lung cancer, especially for the important role of histological definition in therapy-planning process. The results of new biologic agents are also reported as are the promising data on pharmacogenomic-guided treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research